Microbot Medical, Inc. Common Stock (MBOT) is a publicly traded Healthcare sector company. As of July 7, 2026, MBOT trades at $1.91 with a market cap of $128.28M and a P/E ratio of -6.71. MBOT moved -2.59% today. Year to date, MBOT is -5.85%; over the trailing twelve months it is -25.77%. Its 52-week range spans $0.89 to $4.67. Analyst consensus is strong buy with an average price target of $7.17. Rallies surfaces MBOT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Microbot Medical Doubles Q2 Revenue, Sales Territories Rise to Eight and Secures U.S. Federal Contracts: Microbot Medical achieved over 100% sequential revenue and customer growth in Q2 2026 after its April launch of the LIBERTY System at U.S. health systems. Procedure volumes climbed at initial sites, sales territories doubled to eight, and the company secured federal contracts plus Israeli marketing clearance.
| Metric | Value |
|---|---|
| Price | $1.91 |
| Market Cap | $128.28M |
| P/E Ratio | -6.71 |
| EPS | $-0.29 |
| Dividend Yield | 0.00% |
| 52-Week High | $4.67 |
| 52-Week Low | $0.89 |
| Volume | 833.86K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-13.14M |
| Gross Margin | 0.00% |
3 analysts cover MBOT: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $7.17.